Ghanshyam Palamaner Subash Shantha1, Prashant D Bhave1, Saket Girotra1, Denice Hodgson-Zingman1, Alexander Mazur1, Michael Giudici1, Elizabeth Chrischilles1, Mary S Vaughan Sarrazin2. 1. From the Department of Cardiovascular Medicine (G.P.S.S., P.D.B., S.G., D.H.-Z., A.M., M.G.) and Department of Internal Medicine (M.S.V.S.), Roy and Lucille J. Carver College of Medicine and Department of Epidemiology, College of Public Health (E.C.), University of Iowa, Iowa City; and Comprehensive Access and Delivery Research and Evaluation Center, Iowa City VA Medical Center, IA (M.S.V.S.). 2. From the Department of Cardiovascular Medicine (G.P.S.S., P.D.B., S.G., D.H.-Z., A.M., M.G.) and Department of Internal Medicine (M.S.V.S.), Roy and Lucille J. Carver College of Medicine and Department of Epidemiology, College of Public Health (E.C.), University of Iowa, Iowa City; and Comprehensive Access and Delivery Research and Evaluation Center, Iowa City VA Medical Center, IA (M.S.V.S.). mary-vaughan-sarrazin@uiowa.edu.
Abstract
BACKGROUND: Sex-specific comparative effectiveness of direct oral anticoagulants among patients with nonvalvular atrial fibrillation is not known. Via this retrospective cohort study, we assessed the sex-specific, comparative effectiveness of direct oral anticoagulants (rivaroxaban and dabigatran), compared to each other and to warfarin among patients with atrial fibrillation. METHODS AND RESULTS: Elderly (aged ≥66 years) Medicare beneficiaries enrolled in Medicare Part D benefit plan from November 2011 to October 2013 with newly diagnosed atrial fibrillation formed the study cohort (65 734 [44.8%] men and 81 137 [55.2%] women). Primary outcomes of inpatient admissions for ischemic strokes and major bleeding were compared across the 3 drugs (rivaroxaban: 20 mg QD, dabigatran: 150 mg BID, or warfarin) using 3-way propensity-matched samples. In men, rivaroxaban use decreased stroke risk when compared with warfarin use (hazard ratio, 0.69; 95% confidence interval, 0.48-0.99; P=0.048) and dabigatran use (hazard ratio, 0.66; 95% confidence interval, 0.45-0.96; P=0.029) and was associated with a similar risk of any major bleeding when compared with warfarin and dabigatran. In women, although ischemic stroke risk was similar in the 3 anticoagulant groups, rivaroxaban use significantly increased the risk for any major bleeding when compared with warfarin (hazard ratio, 1.20; 95% confidence interval, 1.03-1.42; P=0.021) and dabigatran (hazard ratio, 1.27; 95% confidence interval, 1.09-1.48; P=0.011). CONCLUSIONS: The reduced risk of ischemic stroke in patients taking rivaroxaban, compared with dabigatran and warfarin, seems to be limited to men, whereas the higher risk of bleeding seems to be limited to women.
BACKGROUND: Sex-specific comparative effectiveness of direct oral anticoagulants among patients with nonvalvular atrial fibrillation is not known. Via this retrospective cohort study, we assessed the sex-specific, comparative effectiveness of direct oral anticoagulants (rivaroxaban and dabigatran), compared to each other and to warfarin among patients with atrial fibrillation. METHODS AND RESULTS: Elderly (aged ≥66 years) Medicare beneficiaries enrolled in Medicare Part D benefit plan from November 2011 to October 2013 with newly diagnosed atrial fibrillation formed the study cohort (65 734 [44.8%] men and 81 137 [55.2%] women). Primary outcomes of inpatient admissions for ischemic strokes and major bleeding were compared across the 3 drugs (rivaroxaban: 20 mg QD, dabigatran: 150 mg BID, or warfarin) using 3-way propensity-matched samples. In men, rivaroxaban use decreased stroke risk when compared with warfarin use (hazard ratio, 0.69; 95% confidence interval, 0.48-0.99; P=0.048) and dabigatran use (hazard ratio, 0.66; 95% confidence interval, 0.45-0.96; P=0.029) and was associated with a similar risk of any major bleeding when compared with warfarin and dabigatran. In women, although ischemic stroke risk was similar in the 3 anticoagulant groups, rivaroxaban use significantly increased the risk for any major bleeding when compared with warfarin (hazard ratio, 1.20; 95% confidence interval, 1.03-1.42; P=0.021) and dabigatran (hazard ratio, 1.27; 95% confidence interval, 1.09-1.48; P=0.011). CONCLUSIONS: The reduced risk of ischemic stroke in patients taking rivaroxaban, compared with dabigatran and warfarin, seems to be limited to men, whereas the higher risk of bleeding seems to be limited to women.
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; Paul A Reilly; Lars Wallentin Journal: N Engl J Med Date: 2010-11-04 Impact factor: 91.245
Authors: Timothy W Cutler; Alan Chuang; Tony D Huynh; Robert G Witt; Jennifer Branch; Tiffany Pon; Richard White Journal: J Manag Care Spec Pharm Date: 2014-10
Authors: Steve Deitelzweig; Alpesh Amin; Yonghua Jing; Dinara Makenbaeva; Daniel Wiederkehr; Jay Lin; John Graham Journal: J Med Econ Date: 2013-08-08 Impact factor: 2.448
Authors: Benjamin A Steinberg; Dajuanicia N Holmes; Jonathan P Piccini; Jack Ansell; Paul Chang; Gregg C Fonarow; Bernard Gersh; Kenneth W Mahaffey; Peter R Kowey; Michael D Ezekowitz; Daniel E Singer; Laine Thomas; Eric D Peterson; Elaine M Hylek Journal: J Am Heart Assoc Date: 2013-11-25 Impact factor: 5.501
Authors: Stine Munk Hald; Sören Möller; Luis Alberto García Rodríguez; Rustam Al-Shahi Salman; Mike Sharma; Hanne Christensen; Maja Hellfritzsch; Anton Pottegård; Jesper Hallas; David Gaist Journal: JAMA Netw Open Date: 2021-05-03
Authors: Ching-Lung Cheung; Chor-Wing Sing; Wallis C Y Lau; Gloria H Y Li; Gregory Y H Lip; Kathryn C B Tan; Bernard M Y Cheung; Esther W Y Chan; Ian C K Wong Journal: Cardiovasc Diabetol Date: 2021-03-25 Impact factor: 9.951
Authors: Markus Gulilat; Racquel Jandoc; Nivethika Jeyakumar; Eric McArthur; Amit X Garg; Richard B Kim; Rommel G Tirona; Ute I Schwarz Journal: CJC Open Date: 2021-09-10